RespireRx Signs LOI With Australian CRO For Dronabinol Development For Obstructive Sleep Apnea
RespireRx Pharmaceuticals Inc. (OTCPK:RSPI) entered into a letter of intent with an Australia headquartered bespoke clinical research organization focused on cannabinoid and psychedelic clinical research.